Andrew Barwicki
Investor Relations
Replay available
Biofrontera Inc. (NASDAQ: BFRI) Q1 2025 earnings conference call, held 2025-05-16. Replay captured from the company's public earnings webcast.

Investor Relations
CEO, Chairman and Founder
CFO
Analyst, Roth Capital
Analyst, The Benchmark Company
Good day and welcome to the BioPontera's first quarter of 2025 financial results and business update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Andrew Barwicki. Please go ahead. Good morning and welcome to BioFrontera Incorporated's first quarter fiscal year 2025 financial results and business update conference call. Please note that certain information discussed during today's call by management is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that BioFrontera's management will be making forward-looking statements. and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioFrontier's press releases and SEC filings. Also, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 16, 2025. BioFrontier undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. BioFrontier believes these measures provide...